8-K: Windtree Secures $1.6M Convertible Note Financing

Windtree Therapeutics, Inc. issued $1.6 million in senior convertible promissory notes to institutional investors, maturing in October 2026 with a 10% interest rate.

Summary

• Windtree Therapeutics, Inc. issued $1,600,000 in senior convertible promissory notes due October 9, 2026, to institutional investors.
• The notes bear interest at 10% per annum, payable in cash, with accrued and unpaid interest due on the 5th calendar day of each month, commencing November 5, 2025.
• The notes are convertible, in whole or in part, into shares of common stock at the holder's option.
• The conversion price is set at 90% of the lowest sale price for the 20 consecutive trading days immediately prior to the conversion date.
• The conversion price is subject to automatic downward adjustment to 80% of the lowest sale price over 20 trading days if the current conversion price is higher on specific adjustment dates (Applicable Date, and 10th, 30th, 60th, 90th, 120th, 180th calendar days thereafter).
• A beneficial ownership limitation of 4.99% of the outstanding common stock applies to conversions, which can be increased to 9.99% with 61 days' prior notice from the holder.
• The company must file a resale registration statement on Form S-1 for all registrable securities under the note within 20 calendar days following October 9, 2025.
• Mandatory prepayment is required in an amount equal to 25% of the gross proceeds received from a Common Stock Purchase Agreement dated June 26, 2024, with a 120% premium.
• Full repayment of the notes, including a 120% premium on the note value, is required if the company completes a qualified equity financing of $1,000,000 or more before the maturity date.
• Holders have 'Rollover Rights' to apply outstanding principal and accrued interest as purchase consideration for any future public offering or private placement of equity, equity-linked, or debt securities, converting at 80% of the cash purchase price paid by other investors.
• The notes include customary events of default, which, if triggered, can lead to immediate acceleration of the debt at 120% of the unpaid principal balance, plus accrued interest and liquidated damages, with an additional interest rate of 2% per month (24% per annum).
• The notes are junior to the company's June 2025 Convertible Promissory Note issued to DFU, LLC, which is a senior, unsecured obligation with priority over all existing and future indebtedness.

Sentiment

Score: 4

Explanation: While the financing provides necessary capital, the highly dilutive conversion terms, significant prepayment premiums, and high default interest rates suggest a challenging financial position for the company. The terms are very favorable to the noteholders, indicating a higher risk profile for the issuer and potential negative impact on existing equity holders.

Positives

• Secured $1.6 million in financing, providing essential capital for the company's operations and strategic initiatives.
• The convertible nature of the notes offers potential upside for holders if the company's stock price appreciates.
• Holders benefit from robust anti-dilution provisions and conversion price adjustments based on market price and future equity sales, which protect their investment value.
• Holders have 'Rollover Rights' into future financings at a discounted price (80% of the cash purchase price), offering flexibility and potential for further investment on favorable terms.
• A 'most favorable terms' clause ensures that holders benefit from any better terms offered in future security issuances by the company.

Negatives

• The 10% annual interest rate, coupled with potential late fees of 15% per annum, represents a significant cost of capital for the company.
• Mandatory prepayment obligations with a 120% premium, triggered by proceeds from a prior stock purchase agreement or a qualified financing, could place substantial strain on the company's cash flow.
• The conversion price mechanism (90% of the lowest sale price over 20 days, and automatic adjustment to 80% of market price) is highly dilutive to existing shareholders.
• The notes are junior to the company's June 2025 Convertible Promissory Note, indicating a lower priority in the capital structure in the event of a default or liquidation.
• A broad range of conditions can trigger an Event of Default, leading to immediate acceleration of the debt at a 120% premium and a 24% annual interest rate, posing significant financial risk to the company.
• The requirement to file a resale registration statement on Form S-1 within 20 days suggests an intention for holders to resell shares, potentially increasing selling pressure on the stock.
• The $1,500 review fee for each conversion adds to the company's operational costs.

Risks

• **Dilution Risk:** The aggressive conversion features, including the 90% conversion price and automatic adjustments to 80% of market price, can lead to substantial dilution for existing shareholders.
• **Financial Strain from Prepayments:** Mandatory prepayment obligations with a 120% premium, triggered by future equity financings or proceeds from a prior stock purchase agreement, could create significant cash flow demands on the company.
• **High Cost of Capital:** The 10% interest rate and potential 24% default interest rate represent a high cost of financing, which will negatively impact the company's profitability and financial health.
• **Subordination Risk:** The notes are explicitly junior to other existing debt, specifically the June 2025 Convertible Promissory Note, meaning holders of these notes would have a lower claim on assets in case of liquidation or bankruptcy.
• **Event of Default Risk:** Numerous conditions, including non-payment, covenant breaches, bankruptcy events, trading suspension, or a change of control, can trigger an Event of Default, leading to immediate acceleration of the debt at a premium.
• **Market Price Volatility:** The conversion price adjustments are tied to the company's stock price, making the number of shares issued highly dependent on market performance, which can be volatile and unpredictable.
• **Regulatory Compliance Risk:** Failure to file required SEC reports, such as the Form S-1 registration statement within 20 days, can trigger an Event of Default.
• **Liquidity Risk:** The requirement for the company to deliver physical certificates or book-entry shares within one trading day of conversion, and the penalty for failure to do so, highlights potential liquidity challenges if conversions are frequent.

Future Outlook

The filing indicates that the company anticipates potential future equity financings, which could trigger mandatory prepayment of these notes. It also outlines a commitment to file a resale registration statement for the convertible shares, suggesting an expectation for holders to convert and potentially sell shares in the future. The 'most favorable terms' clause implies the company may seek additional financing with potentially different terms in the future.

Management Comments

• Jed Latkin, CEO, signed the report on behalf of Windtree Therapeutics, Inc., indicating management's formal acknowledgment and approval of the transaction.

Industry Context

This financing structure, involving convertible notes with significant anti-dilution and downside protection for investors, is common for smaller biotechnology or pharmaceutical companies like Windtree Therapeutics, Inc. that require capital for R&D or operational expenses but may face challenges securing traditional debt or equity due to their stage of development or market volatility. The terms suggest a need for capital and a willingness to offer favorable terms to investors to secure it, which is typical in the high-risk, high-reward biotech sector where access to capital is paramount for survival and growth.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution due to the convertible nature of the notes and the aggressive conversion price adjustment mechanisms (90% and 80% of market price). Existing shareholders' equity value could be eroded.
• **Creditors:** The new notes are junior to the June 2025 Convertible Promissory Note, impacting their recovery priority in a default scenario. Other creditors' positions are not explicitly detailed but could be affected by the company's overall debt burden.
• **Company (Management/Operations):** Provides immediate capital to fund operations or strategic initiatives, but at a high cost and with restrictive covenants that could limit future financial flexibility. The risk of default and accelerated repayment at a premium adds pressure.
• **Noteholders:** Benefit from strong downside protection (conversion price adjustments, default premiums) and potential upside through conversion into equity. They also have flexibility with rollover rights into future financings.

Next Steps

• The Company must file a resale registration statement on Form S-1 within 20 calendar days following October 9, 2025, for the registrable securities.
• Interest payments on the notes are due on the 5th calendar day of each month, commencing November 5, 2025.
• The Company may need to make mandatory prepayments from proceeds of a prior Common Stock Purchase Agreement.
• The Company may undertake a 'Qualified Financing' of $1,000,000 or more, which would trigger full repayment of these notes.
• The Company must notify holders of any dilutive issuances or other events affecting the conversion price.

Key Dates

Recommendation

While the financing addresses immediate capital needs, the highly dilutive terms of the convertible notes, including aggressive conversion price adjustments and significant prepayment premiums, pose substantial risks to existing shareholders. The high cost of capital and numerous events of default could lead to further financial strain. Investors should hold to monitor the company's ability to manage this debt, execute its strategy, and avoid further dilution, but the terms are not favorable enough to warrant a 'buy' given the inherent risks.

Keywords

Windtree Therapeutics, Convertible Promissory Note, SEC Filing, 8-K, Debt Financing, Equity Financing, Dilution, Corporate Governance, Financial Obligation, WINT, Biotechnology, Pharmaceuticals